| Literature DB >> 31416571 |
Klara Cervena1, Pavel Vodicka2, Veronika Vymetalkova2.
Abstract
The development of minimally invasive and low-cost assay enabling early diagnosis, treatment response and prognosis in cancer patients may provide a promising alternative to tumor biopsy. Circulating cell-free DNA (cfDNA) is probably the most promising tool among all components of liquid biopsy. This review includes studies exploring cfDNA as the diagnostic, prognostic or predictive biomarker for all types of cancer. In this article, we systematically reviewed the relevant literature from PubMed about cfDNA. All articles presented higher cfDNA concentration in cancer patients when compared with patients with benign disease or healthy individuals. Most of the articles showed a connection between cfDNA and prognosis. The presence of high cfDNA level in serum or plasma was associated with worse overall patient's survival. This review supports the idea that the cfDNA analysis represents a promising research area and hopefully in the future, could be applied as a new biomarker for cancer detection, prognosis determination and prediction of the response to therapy.Entities:
Keywords: Biomarker; Cancer; Cell-free DNA; Circulating-tumor DNA; Liquid biopsy
Mesh：
Substances：
Year: 2019 PMID： 31416571 DOI： 10.1016/j.mrrev.2019.05.002
Source DB: PubMed Journal: Mutat Res Rev Mutat Res ISSN： 1383-5742 Impact factor: 5.657